Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fate Therapeutics' Leadership Changes

This article was originally published in Scrip

Executive Summary

Fate Therapeutics has appointed Scott Wolchko president and CEO following Christian Weyer's resignation – effective Nov. 30, 2015. Wolchko, who was chief financial officer (CFO) since the company was found in 2007 and chief operating officer since January 2013, has also joined Fate's board of directors. Prior to Fate, Wolchko was CFO of an enterprise software company, Bocada Inc. In addition to Wolchko's appointment, Dr. Daniel Shoemaker has been promoted to chief scientific officer from chief technology officer; Dr. Stewart Abbot, formerly vice-president of translational research, has been named chief development officer; and Cindy Tahl has been promoted to general counsel after being the company's senior legal counsel since 2009.

You may also be interested in...

Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?

How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.

Adherence Issues Add Weight To Digital Trials Push

Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.

Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus

This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts